Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 20/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 13/20 | 0.49 |
| ▸ | KIT | P10721 | 3/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.47 |
| ▸ | FLT3 | P36888 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30086983 | 0.88 | CSF1R (0.59) | CSF1RPDGFRAKITPDGFRBFLT3 | |
| SCHEMBL21426311 | 0.88 | CSF1R (0.59) | CSF1RPDGFRAKITPDGFRBFLT3 | |
| SCHEMBL28341064 | 0.86 | CSF1R (0.49) | CSF1RPDGFRAKITPDGFRBFLT3 | |
| SCHEMBL16029505 | 0.83 | CSF1R (0.61) | CSF1RPDGFRAKITPDGFRBFLT3 | |
| SCHEMBL16059552 | 0.83 | CSF1R (0.61) | CSF1RPDGFRAKITPDGFRBFLT3 | |
| SCHEMBL16028609 | 0.82 | CSF1R (0.52) | CSF1RPDGFRAKITPDGFRBFLT3 | |
| SCHEMBL16028387 | 0.81 | CSF1R (0.57) | CSF1RPDGFRAKITPDGFRBFLT3 | |
| SCHEMBL30086819 | 0.81 | CSF1R (0.57) | CSF1RPDGFRAKITPDGFRBFLT3 | |
| SCHEMBL16028875 | 0.81 | CSF1R (0.55) | CSF1RPDGFRAKITPDGFRBFLT3 | |
| SCHEMBL16060930 | 0.81 | CSF1R (0.67) | CSF1RPDGFRAKITPDGFRBFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632907-B1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-3632907-B1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-11149021-B2 | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-10-19 | — | — | US | disclosed |
| US-11149021-B2 | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-10-19 | — | — | US | disclosed |
| CN-112047927-A | N-acyl-N' - (pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activity | 德西费拉制药有限责任公司 | 2020-12-08 | — | — | CN | disclosed |
| CN-105228620-B | N-acyl-N' - (pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activity | 德西费拉制药有限责任公司 | 2020-09-04 | — | — | CN | disclosed |
| EP-2968287-B1 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS LLC (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3632907-A1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2020-04-08 | — | — | EP | disclosed |
| EP-3632907-A1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2020-04-08 | — | — | EP | disclosed |
| US-20200071302-A1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2020-03-05 | — | — | US | disclosed |
| US-20160046619-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS LLC (US) | 2016-02-18 | — | — | US | disclosed |
| EP-2968287-A2 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | Deciphera Pharmaceuticals, LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9193719-B2 | 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2015-11-24 | — | — | US | disclosed |
| US-9133183-B2 | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140315917-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140296252-A1 | 1,2,4-TRIAZOL-5-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140275080-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014145015-A2 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145023-A1 | 1,2,4-TRIAZOL-5-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145028-A2 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275080-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | KIT, CSF1R, CSF3R | CSF1R 2/4885PDGFRA 5/4885KIT 1/4885 |
| US-20200071302-A1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | CSF1R, CSF3R, FAR1 | CSF1R 1/4885PDGFRA 586/4885KIT 195/4885 |
| US-20160046619-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | CSF1R, KIT, CSF3R | CSF1R 1/4885PDGFRA 5/4885KIT 2/4885 |
| US-11149021-B2 | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | CSF1R, CSF3R, FAR1 | CSF1R 1/4885PDGFRA 586/4885KIT 195/4885 |
| US-20140315917-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | CSF1R, KIT, CSF3R | CSF1R 1/4885PDGFRA 5/4885KIT 2/4885 |
| US-20140296252-A1 | 1,2,4-TRIAZOL-5-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | KIT, CSF1R, CSF3R | CSF1R 2/4885PDGFRA 5/4885KIT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.